Review of atrial fibrillation outcome trials of oral anticoagulant and antiplatelet agents.

Europace · 2012 · PMC3283221 · PMID 22355190

Europe PMC DOI

hedged sentence

0.0900

closest p · 1.8× alpha

0.0900

boldest claim

The sentences

did not reach statistical significanceP = 0.09so close (0.05 < p ≤ 0.1)

A greater number of myocardial infarctions was seen with both the 110 mg and 150 mg bid dose of dabigatran (98 and 97 events, respectively) compared with warfarin (75 events), although this did not reach statistical significance [110 mg vs. warfarin: RR 1.29 (95% CI 0.96–1.75; P = 0.09); 150 mg vs. warfarin: RR 1.27 (95% CI 0.94–1.71); P = 0.12].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.